WO2024085427A1 - Polymer nanodiscs comprising angiotensin-converting enzyme 2 and antiviral use thereof - Google Patents

Polymer nanodiscs comprising angiotensin-converting enzyme 2 and antiviral use thereof Download PDF

Info

Publication number
WO2024085427A1
WO2024085427A1 PCT/KR2023/013151 KR2023013151W WO2024085427A1 WO 2024085427 A1 WO2024085427 A1 WO 2024085427A1 KR 2023013151 W KR2023013151 W KR 2023013151W WO 2024085427 A1 WO2024085427 A1 WO 2024085427A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
glycero
converting enzyme
nanodisc
ace2
Prior art date
Application number
PCT/KR2023/013151
Other languages
French (fr)
Korean (ko)
Inventor
권대혁
김미수
황재현
Original Assignee
성균관대학교산학협력단
엠브릭스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단, 엠브릭스 주식회사 filed Critical 성균관대학교산학협력단
Publication of WO2024085427A1 publication Critical patent/WO2024085427A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to polymer nanodiscs containing a lipid bilayer, an amphipathic polymer, and angiotensin converting enzyme 2 (ACE2), and their antiviral use.
  • ACE2 angiotensin converting enzyme 2
  • Influenza virus is an RNA virus belonging to the Orthomyxoviridae family and is divided into three serotypes: type A, type B, and type C. Among them, types B and C have been confirmed to infect only humans, while type A has been confirmed to infect humans, horses, pigs, other mammals, and various types of poultry and wild birds.
  • the serotypes of influenza A virus are classified according to the types of two proteins on the surface of the virus, hemagglutinin (HA) and neuraminidase (NA). There are currently 144 types (16 types of HA proteins). and 9 types of NA proteins) are known. HA plays a role in allowing the virus to attach to body cells, and NA allows the virus to penetrate into cells.
  • Treatments for viral infections that have been developed so far include amantadine or rimantadine-type M2 ion channel inhibitors and oseltamivir (brand name Tamiflu) or zanamivir (brand name Relenza). ) series of neuraminidase inhibitors are known, but these treatments have a problem in that their effectiveness is limited.
  • oseltamivir brand name Tamiflu
  • zanamivir brand name Relenza
  • neuraminidase inhibitors are known, but these treatments have a problem in that their effectiveness is limited.
  • resistant mutant viruses are quickly generated, the H5N1 type influenza virus detected in some regions shows resistance to amantadine or rimantadine series compounds, and influenza B virus is amantadine-based. It is known to be insensitive to derivatives.
  • the number of resistant viruses against oseltamivir or zanamivir derivative compounds is increasing, and such resistant viruses are frequently occurring in children.
  • Korean Patent No. 1334143 discloses Polygala karensium extract and isolates thereof.
  • a composition for preventing or treating colds, avian influenza, swine influenza, or swine flu containing a xanthone-based compound is disclosed.
  • these agents have low anti-viral activity and do not show effective prevention or treatment of influenza-derived diseases such as swine flu.
  • Coronavirus is an RNA virus belonging to the Coronavirinae family of the Coronaviridae family, which causes respiratory and digestive system infections in humans and animals. It is mainly transmitted through mucous membrane infection and droplet transmission, and generally causes mild respiratory infections in humans, but can also cause fatal infections. It can also cause diarrhea in cattle and pigs, and respiratory disease in chickens. Coronavirus is a representative virus that causes fatal infectious diseases in modern civilization.
  • Severe Acute Respiratory Syndrome also known as SARS, broke out in the People's Republic of China, killing many people with a mortality rate of 9.6%.
  • Middle East Respiratory Syndrome also known as MERS, spread from the Middle East to the world, causing many deaths with a mortality rate of about 36%.
  • Angiotensin converting enzyme 2 plays an important role in the Renin-angiotensin-aldosterone system (RAAS), which regulates body moisture and blood pressure.
  • RAAS Renin-angiotensin-aldosterone system
  • renin converts angiotensinogen into angiotensin I
  • ACE angiotensin converting enzyme
  • Angiotensin II has a direct ‘adverse effect’ on the cardiovascular system, including inflammatory reactions within blood vessels and promoting atherosclerosis.
  • angiotensin II in the body is converted to angiotensin (1-7) by ACE2, and as a result, homeostasis can be maintained. Therefore, ACE2 can be said to be an important enzyme in maintaining body homeostasis.
  • ACE2 has a transmembrane site and exists in the body by being incorporated into the cell membrane. Due to the above characteristics, many studies have recently been reported on the possibility of using soluble ACE2 (soluble ACE2, sACE2) as an antiviral agent, such as preventing viral infection or suppressing the proliferation of infected viruses. ACE2 (recombinant soluble ACE2, rsACE2) is also being developed. Nevertheless, antiviral drugs using soluble ACE2 have limitations due to low in vivo antiviral efficacy.
  • the membrane scaffold protein (MSP) in the existing nanodisk structure has low stability to heat and low resistance to proteolytic enzymes in the body
  • MSP membrane scaffold protein
  • the present invention is a flat disk-shaped bilayer structure formed using phospholipids, a lipid bilayer in which the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside; an amphipathic polymer that surrounds the ‘side where the hydrophobic group is exposed to the outside’ of the lipid bilayer with a hydrophobic bond; and angiotensin converting enzyme 2 (ACE2) hydrophobically bound to the inside of the lipid bilayer.
  • ACE2 angiotensin converting enzyme 2
  • the transmembrane domain of the angiotensin converting enzyme 2 is preferably bound to a hydrophobic portion of the lipid bilayer.
  • the phospholipid may be, for example, one or more selected from phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phophatidylglycerol, and phosphatidylinositol.
  • DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine
  • DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
  • DSPC 1,2-distearoyl-sn- glycero-3-phosphocholine
  • POPC l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
  • DOPS 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
  • POPE It is recommended to include at least one selected from 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine).
  • the amphipathic polymer is preferably Styrene-Maleic Acid (SMA) or Di-IsoButylene-Maleic Acid (DIBMA). ), Styrene-Maleimide (SMI), and polymethyl methacrylate (PMA).
  • SMA Styrene-Maleic Acid
  • DIBMA Di-IsoButylene-Maleic Acid
  • SI Styrene-Maleimide
  • PMA polymethyl methacrylate
  • the angiotensin converting enzyme 2 may be water-soluble angiotensin converting enzyme 2.
  • the present invention provides a pharmaceutical composition for preventing or treating viral infections, comprising the polymer nanodisc of the present invention.
  • the polymer nanodisc containing the lipid bilayer, amphiphilic polymer, and angiotensin converting enzyme 2 of the present invention has excellent antiviral efficacy. Accordingly, the polymer nanodisc of the present invention can be used as a pharmaceutical composition for preventing or treating viral infections.
  • the polymer nanodisc of the present invention replaces the membrane scaffold protein (MSP) used in existing nanodiscs with a polymer component, enabling excellent structural stability and more economical production.
  • MSP membrane scaffold protein
  • Figure 1 schematically shows the structure of the polymer nanodisk of the present invention.
  • Figure 2 shows the results of size exclusion chromatography to purify a concentrate containing the polymer nanodisc of the present invention.
  • FIG 3 shows a nanodisk (MSPNDA) containing an existing membrane scaffold protein (MSP) and a polymer nanodisk (SMANDA) of the present invention in which the membrane scaffold protein (MSP) is replaced with a polymer component. This is the result of comparing antiviral efficacy.
  • MSPNDA nanodisk
  • SMANDA polymer nanodisk
  • the present invention is a flat disk-shaped bilayer structure formed using phospholipids, a lipid bilayer in which the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside; an amphipathic polymer that surrounds the ‘side where the hydrophobic group is exposed to the outside’ of the lipid bilayer with a hydrophobic bond; and angiotensin converting enzyme 2 (ACE2) hydrophobically bound to the inside of the lipid bilayer.
  • ACE2 angiotensin converting enzyme 2
  • the present inventor has developed nanodiscs with excellent antiviral efficacy using membrane scaffold protein (MSP) and ACE2 as a viral receptor. Later, while developing a technology to manufacture the nanodisk more simply and economically, the present invention developed a technology to manufacture nanodiscs by replacing the membrane structural protein (MSP) in the nanodisk with an amphipathic polymer component. was developed.
  • the nanodisc of the present invention developed in this way showed antiviral activity like the nanodisc of Korean Patent No. 10-2438720, which was previously manufactured using MSP and ACE2.
  • styrene and maleic acid were used as an amphiphilic polymer in a weight ratio of 2:1 to replace MSP, it was confirmed that the antiviral efficacy was almost similar to that of nanodiscs made with MSP.
  • the polymer nanodisc of the present invention manufactured by replacing MSP with an amphiphilic polymer, has the great advantage of being very economical and simplifying the manufacturing process due to its high thermal stability and low manufacturing cost because the protein is replaced with a polymer component.
  • the lipid bilayer of the present invention is a flat disk-shaped bilayer structure formed using phospholipids, and is characterized in that the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside. That is, the lipid bilayer of the present invention is in the form of a disk (see Figure 1) with not only the hydrophilic portion of the phospholipid, but also the hydrophobic portion exposed to the outside through the side, so that it can be selectively selected between the hydrophilic or hydrophobic portion. Only one is structurally different from the sphere-shaped liposome exposed to the outside.
  • the phospholipid of the present invention may be one or more selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol.
  • the phosphatidylcholine is, for example, DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine), DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine), DMPC (1,2-Dimyristoyl- sn-glycero-3-phosphocholine), DPPC (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine), POPC (1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), C13PC, DDPC (1 ,2-Didecanoyl-sn-glycero-3-phosphocholine), DSPC(1,2-Distearoyl-sn-glycero-3-phosphocholine), DEPC(1,2-Dierucoyl-sn-glycero-3-phosphocholine), DLOPC( 1,2-Dilinoleoyl-sn-glycero-3
  • the phosphatidyl glycerol is, for example, DMPG (1,2-Dimyristoyl-sn-glycero-3[Phospho-rac-(1-glycerol)], DPPG (1,2-Dipalmitoyl-sn-glycero-3[Phospho-rac) -(1-glycerol)]), DSPG(1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)), POPG(1-Palmitoyl-2-oleoyl-sn-glycero-3[ Phospho-rac-(1-glycerol)]), DEPG(1,2-Dierucoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DLPG(1,2-Dilauroyl-sn-glycero- 3[Phospho-rac-(1-glycerol)]), DOPG(1,
  • the amphipathic polymer of the present invention has amphipathic properties and thus serves to prevent the hydrophobic tail (acyl tail) from being directly exposed to water.
  • this amphiphilic polymer When this amphiphilic polymer is present in a certain ratio, the polymer wraps around the middle layer of phospholipids (two-layer hydrophobic acyl tails) forming a lipid bilayer. As a result, the disk-shaped lipid bilayer shape is stabilized in aqueous solution. At this time, the size of the lipid bilayer disk is determined depending on the phospholipid:polymer ratio.
  • amphipathic polymer of the present invention is preferably styrene-maleic acid (SMA), di-Isobutylene-maleic acid (DIBMA), or styrene-maleic acid. It is better to use at least one selected from styrene-maleimide (SMI) and polymethyl methacrylate (PMA).
  • SMA styrene-maleic acid
  • DIBMA di-Isobutylene-maleic acid
  • PMA polymethyl methacrylate
  • the SMA is a copolymer obtained by polymerizing styrene and maleic acid, and can be polymerized using a polymerization method widely known in the art. At this time, SMA can be additionally modified with ethanolamine, ethylenediamine, quaternary ammonium, sulfhydryl, etc.
  • the polymer nanodisc of the present invention is characterized in that Angiotensin converting enzyme 2 (ACE2) is bound to a lipid bilayer (see Figure 1).
  • Angiotensin converting enzyme 2 (ACE2) has a hydrophobic transmembrane domain at the C-terminus, and this region meets the hydrophobic region of the lipid bilayer and forms a hydrophobic bond.
  • the angiotensin converting enzyme 2 may be water-soluble angiotensin converting enzyme 2.
  • ACE2 angiotensin-converting enzyme 2
  • ACE2 has a transmembrane site and exists embedded in the cell membrane using this site.
  • soluble ACE2 recombinant soluble ACE2, rsACE2
  • the water-soluble ACE2 developed in this way can also be used.
  • the present invention provides a pharmaceutical composition for preventing or treating viral infections, comprising the nanodisc of the present invention.
  • “viral infection” includes, for example, renal syndrome hemorrhagic fever (epidemic hemorrhagic fever) caused by infection with a virus of the Verniaviridae family; Respiratory diseases such as nasal colds or coronavirus infections caused by infection with viruses of the Coronaviridae family; Hepatitis C caused by infection with viruses of the Flaviviridae family; Hepatitis B caused by infection with viruses of the Hepadnaviridae family; Shingles caused by infection with viruses of the Herpesviridae family; Flu or influenza virus infection caused by infection with a virus of the Orthomyxoviridae family; Smallpox caused by infection with viruses of the Poxviridae family; Rabies or vesicular stomatitis caused by infection with viruses of the Rhabdoviridae family; It can be an acquired immunodeficiency syndrome caused by infection with a virus of the retroviridae family, and as another example, it can be a flu or
  • coronavirus infection that has a spike protein that can bind to angiotensin converting enzyme 2 (ACE2).
  • ACE2 angiotensin converting enzyme 2
  • coronaviruses including SARS-CoV-2, use angiotensin-converting enzyme 2 as a receptor, and are known to have the ability to bind to angiotensin-converting enzyme 2.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the composition as an active ingredient.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in preparation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, and calcium silicate. , microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, etc. no.
  • the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, for example, intrathecal administration, intravenous administration, subcutaneous administration, intradermal administration, intramuscular administration, intraperitoneal administration, intrasternal administration, intratumoral administration, intranasal administration, It can be administered by intracerebral administration, intracranial administration, intrapulmonary administration, and intrarectal administration, but is not limited thereto.
  • the appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is usually A skilled doctor can easily determine and prescribe an effective dosage (pharmaceutically effective amount) for desired treatment or prevention.
  • the daily dosage of the pharmaceutical composition of the present invention is 0.0001-100 mg/kg.
  • pharmaceutically effective amount of the present invention means an amount sufficient to prevent or treat the above-mentioned disease.
  • the term “prophylaxis” refers to the prevention or protective treatment of a disease or disease state.
  • treatment means reducing, suppressing, alleviating or eradicating a disease state.
  • the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using pharmaceutically acceptable carriers and/or excipients according to a method that can be easily performed by those skilled in the art. It can be manufactured by placing it in a multi-capacity container. At this time, the dosage form can be manufactured in a variety of ways, such as oral medicine or injection, and can be in the form of a solution, suspension or emulsion in oil or aqueous medium, or in the form of extract, powder, suppository, powder, granule, tablet or capsule, and may be in the form of a dispersant or stabilizer. Additional topics may be included.
  • HEK293 Human embryonic kidney 293 soluble suspension cells were cultured at 37°C, 120 rpm, and 8% CO 2 to prepare 1.1 ⁇ 10 6 cells/mL, 180 mL.
  • ACE2 human-derived Angiotensin converting enzyme 2
  • PEI poly ethylenimine
  • the cells were cultured in an incubator at 37°C, 120 rpm, and 8% CO 2 for 72 hours, and then centrifuged at 8000 g for 10 minutes to remove the medium and obtain only the cells.
  • the cells were resuspended using Tris buffer containing 1% DDM, membrane proteins were separated using an ultra-high-speed centrifuge, and purified using Ni-NTA agarose beads. Afterwards, substances that failed to bind to the beads were removed using a buffer containing 0.1% DDM and a low concentration of imidazole, and angiotensin converting enzyme 2 (ACE2) (SEQ ID NO. 2) was obtained.
  • ACE2 angiotensin converting enzyme 2
  • soluble angiotensin converting enzyme 2 (Soluble ACE2; sACE2) was transfected using a plasmid containing the soluble ACE2 gene (SEQ ID NO: 3) in the above method, under the conditions of 37°C, 120 rpm, and 8% CO 2. After culturing the cells in an incubator for 72 hours, the cells were removed by centrifugation at 8000 ⁇ g for 10 minutes, and the supernatant was purified using Ni-NTA agarose beads.
  • polymers In order to manufacture the polymer nanodisc of the present invention, two types of polymers were used as amphiphilic polymers, in which Styrene:Maleic acid of SMA (Styrene-Maleic Acid) was polymerized at a molar ratio of 2:1 or 3:1.
  • SMA Styrene-Maleic Acid
  • POPC l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
  • Polymer and lipid were used at a weight ratio of 1:2.
  • the manufacturing method of the polymer nanodisk of the present invention is specifically as follows.
  • lipids in the form of solid powder were dissolved in an organic solvent, the lipids were mixed in a glass tube, and the organic solvent was completely vaporized using nitrogen gas and a vacuum tube, leaving only the lipids in the form of a film.
  • hydration buffer (10mM HEPES, 150mM NaCl; pH 7.4)
  • freeze and thaw processes were performed more than 5 times using liquid nitrogen and water at 50°C to generate liposomes. did.
  • a membrane with a size of 100 nm is inserted into the extrusion device, and the liposome solution is repeatedly passed to the left and right of the membrane using pressure to adjust the liposome diameter to 100 nm or less.
  • the tritonX-100 reagent to a concentration of 2mM, react for 1 hour.
  • ACE2 Angiotensin converting enzyme 2
  • beads were added at a concentration of 80 mg/ml and reacted at room temperature for 2 hours to remove tritonX-100. After processing the clean beads twice, the beads are separated by centrifugation.
  • the polymers were added so that the w/w ratio of each polymer (two types of SMA 2:1 and SMA 3:1) and lipid was 1:2, and then frozen and sonicated using liquid nitrogen and a sonicator at 50°C. The process was performed three times. Through this, as the polymer penetrates the liposome, water molecules enter and form pores between the lipid layers, ultimately forming a nanodisk structure. Ultracentrifugal filtration was performed to remove polymers that did not form nanodisks and liposomes with large diameters to obtain a concentrate. Afterwards, the nanodisc concentrate was purified according to size through size exclusion chromatography ( Figure 2), and the obtained sample was concentrated to obtain a polymer nanodisc (SMANDA) concentrate containing ACE2.
  • SMANDA polymer nanodisc
  • the average diameter when SMA (2:1) was added was found to be 13.31 nm, and when SMA (3:1) was added, the average diameter was 9.71 nm. appear.
  • the degree of infection of SARS-CoV-2-pseudovirus (PV) was quantified in “HEK293-ACE2/TMPRSS2”, which is a cell that simultaneously expressed ACE2 and TMPRSS2 (Transmembrane protease serine subtype 2) in 293T cells.
  • the virus inhibition ability was evaluated using the following method.
  • the control group was set as a nanodisc containing ACE2 (MSPNDA), which was manufactured from membrane scaffold protein (MSP) rather than a polymer component.
  • MSPNDA nanodisc containing ACE2
  • MSP membrane scaffold protein
  • 293T cells were dispensed at 2 Meanwhile, mix the drug (nanodisc concentrate) and coronavirus-pseudovirus (1 ⁇ 10 5 RLU, Relative Light Unit) at a ratio of 1:2, but the concentration of the drug is Angiotensin converting enzyme 2 (ACE2). ) was diluted and mixed starting from 100 ⁇ M, and reacted at 37°C in a 5% CO 2 incubator for 1 hour. Afterwards, a 96-well plate containing 293T cells was treated with the 'nanodisk + virus mixture' reacted for 1 hour, and then cultured in an incubator at 37°C and 5% CO 2 for 48 hours.
  • ACE2 Angiotensin converting enzyme 2
  • the polymer nanodisc (SMANDA) of the present invention which replaces membrane scaffold protein (MSP) with a polymer component, also shows excellent antiviral efficacy against coronavirus like MSPNDA.
  • SMANDA 2:1 membrane scaffold protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to: polymer nanodiscs comprising a lipid bilayer, an amphiphilic polymer, and angiotensin-converting enzyme 2 (ACE2); and antiviral use thereof, and exhibits good antiviral efficacy despite the replacement of the membrane scaffold protein (MSP) used in conventional nanodisc preparation with an amphiphilic polymer component.

Description

안지오텐신 전환효소 2를 포함하는 폴리머 나노디스크 및 이의 항바이러스 용도Polymer nanodisc containing angiotensin converting enzyme 2 and antiviral use thereof
본 발명은 지질 이중층, 양친매성 폴리머 및 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)를 포함하는 폴리머 나노디스크 및 이의 항바이러스 용도에 관한 것이다.The present invention relates to polymer nanodiscs containing a lipid bilayer, an amphipathic polymer, and angiotensin converting enzyme 2 (ACE2), and their antiviral use.
인플루엔자 바이러스(Influenza virus)는 오르소믹소 계통(Family Orthomyxoviridae)에 속하는 RNA 바이러스로서 혈청형은 A형, B형, C형 등 3가지로 구분된다. 그 중 B형과 C형은 사람에서만 감염이 확인되고 있으며, A형은 사람, 말, 돼지, 기타 포유류 그리고 다양한 종류의 가금과 야생조류에서 감염이 확인되고 있다. A형 인플루엔자 바이러스의 혈청형은 바이러스 표면의 두 가지 단백질인 헤마글루티닌(Hemagglutinin; HA)과 뉴라미니다제(Neuraminidase;NA)의 종류에 따라 구분되는데, 지금까지 144종류(HA 단백질 16종과 NA 단백질 9종)가 알려져있다. HA는 바이러스가 체세포에 부착하는 역할을 하며, NA는 바이러스가 세포 내로 침투할 수 있도록 한다.Influenza virus is an RNA virus belonging to the Orthomyxoviridae family and is divided into three serotypes: type A, type B, and type C. Among them, types B and C have been confirmed to infect only humans, while type A has been confirmed to infect humans, horses, pigs, other mammals, and various types of poultry and wild birds. The serotypes of influenza A virus are classified according to the types of two proteins on the surface of the virus, hemagglutinin (HA) and neuraminidase (NA). There are currently 144 types (16 types of HA proteins). and 9 types of NA proteins) are known. HA plays a role in allowing the virus to attach to body cells, and NA allows the virus to penetrate into cells.
지금까지 개발된 바이러스 감염증 치료제로는 아만타딘(amantadine) 또는 리만타딘(rimantadine)계열의 M2 이온채널 억제제(M2 ion channel inhibitor)와 오셀타미비르(oseltamivir, 상품명 타미플루) 또는 자나미비르(zanamivir, 상품명 리렌자) 계열의 뉴라미니데이즈(neuraminidase) 억제제가 알려져 있으나, 이들 치료제는 그의 효과가 제한된다는 문제점이 있었다. 즉, 아만타딘 또는 리만타딘 계열의 유도체 화합물은 이에 대한 저항성 변종바이러스가 빠르게 생성되고, 일부 지역에서 검출된 H5N1 타입의 인플루엔자 바이러스는 아만타딘 또는 리만타딘 계열의 화합물에 대하여 내성을 나타내며, 인플루엔자 B 바이러스는 아만타딘 유도체에 민감하지 않다고 알려져 있다. 또한, 오셀타미비르 또는 자나미비르 계열의 유도체 화합물 역시 이에 대한 저항성 바이러스가 증가하고, 이러한 저항성 바이러스는 어린이에게서 빈번히 발생하고 있다고 알려져 있다.Treatments for viral infections that have been developed so far include amantadine or rimantadine-type M2 ion channel inhibitors and oseltamivir (brand name Tamiflu) or zanamivir (brand name Relenza). ) series of neuraminidase inhibitors are known, but these treatments have a problem in that their effectiveness is limited. In other words, for amantadine or rimantadine series derivative compounds, resistant mutant viruses are quickly generated, the H5N1 type influenza virus detected in some regions shows resistance to amantadine or rimantadine series compounds, and influenza B virus is amantadine-based. It is known to be insensitive to derivatives. In addition, it is known that the number of resistant viruses against oseltamivir or zanamivir derivative compounds is increasing, and such resistant viruses are frequently occurring in children.
상기와 같은 기존 바이러스 감염증 치료의 문제점이 없는 새로운 치료제를 개발하기 위한 연구가 활발히 진행되고 있는데, 예를 들어, 한국등록특허 제1334143호에는 폴리갈라 카렌시움(Polygala karensium) 추출물 및 이로부터 분리된 잔톤계 화합물을 함유하는 감기, 조류 인플루엔자, 돼지 인플루엔자 또는 신종플루의 예방 또는 치료용 조성물이 개시되어 있다. 그러나, 이들 제제는 항-바이러스 활성이 낮아서, 신종플루와 같은 인플루엔자 유래 질병에 대한 효과적인 예방 또는 치료효과를 나타내지는 못하고 있다.Research is actively underway to develop new treatments that do not have the problems of treating existing viral infections as described above. For example, Korean Patent No. 1334143 discloses Polygala karensium extract and isolates thereof. A composition for preventing or treating colds, avian influenza, swine influenza, or swine flu containing a xanthone-based compound is disclosed. However, these agents have low anti-viral activity and do not show effective prevention or treatment of influenza-derived diseases such as swine flu.
또한, 2015년에는 코로나 바이러스에 의한 메르스, 2020년부터 현재 진행형인 코로나 바이러스에 의한 COVID-19 등 바이러스에 의한 질병의 유행이 근래 다수 발생하고 있다. In addition, many epidemics of diseases caused by viruses have occurred in recent years, such as MERS caused by a coronavirus in 2015 and COVID-19 caused by a coronavirus that has been ongoing since 2020.
코로나바이러스는　코로나바이러스과(Coronaviridae)의　코로나바이러스아과(Coronavirinae)에 속하는　RNA 바이러스로,　사람과 동물의 호흡기와 소화기계 감염을 유발한다. 주로 점막전염, 비말전파로 쉽게 감염되며, 사람에게는 일반적으로 경미한　호흡기 감염을 일으키지만 치명적인 감염을 유발하기도 하며, 소와 돼지는 설사, 닭은 호흡기 질환이 발생하기도 한다. 코로나바이러스는 현대 문명에서 치명적인 감염병을 일으키는 대표적인 바이러스다.　2003년　4월에는　중화인민공화국발　중증급성호흡기증후군,　일명 사스가 유행해 사망률 9.6%를 기록하며 많은 사람이 사망했다.　2015년에는　중동호흡기증후군, 일명 메르스가　중동에서 전 세계로 퍼지면서 사망률 약 36%로써 사망자가 다수 발생하였다. 또한　2019년　12월부터 중국 우한발　신종 코로나바이러스 감염증(코로나19,COVID-19)이 전 세계로 확진되면서 감염자가 늘어나고 있으며, 치사율은 2020년 2월까지 집계된 자료에 따르면 2.6%로 그나마 낮은 편이지만 전세계에서 확진자가 폭증하는 중이며 예방 또는 치료 목적으로 승인된 백신이나 항바이러스제는 없었다.　현재, 카모스타트, 렘데시비르, 하이도록시클로로퀸 등의 타 질환치료제로 이용되던 약물들이 코로나바이러스 치료제로의 가능성에 대해서 검토되고, 부작용과 미미한 효능으로 인하여 임상이 실패하거나 정지되어 있다.Coronavirus is an RNA virus belonging to the Coronavirinae family of the Coronaviridae family, which causes respiratory and digestive system infections in humans and animals. It is mainly transmitted through mucous membrane infection and droplet transmission, and generally causes mild respiratory infections in humans, but can also cause fatal infections. It can also cause diarrhea in cattle and pigs, and respiratory disease in chickens. Coronavirus is a representative virus that causes fatal infectious diseases in modern civilization. In April 2003, Severe Acute Respiratory Syndrome, also known as SARS, broke out in the People's Republic of China, killing many people with a mortality rate of 9.6%. In 2015, Middle East Respiratory Syndrome, also known as MERS, spread from the Middle East to the world, causing many deaths with a mortality rate of about 36%. In addition, as the new coronavirus infection (COVID-19) from Wuhan, China has been confirmed worldwide since December 2019, the number of infected people has been increasing, and the fatality rate is relatively low at 2.6% according to data collected through February 2020. However, the number of confirmed cases is rapidly increasing around the world, and there are no vaccines or antiviral drugs approved for prevention or treatment. Currently, drugs used to treat other diseases, such as camostat, remdesivir, and hydroxychloroquine, are being reviewed for their potential as coronavirus treatments, and clinical trials have failed or been halted due to side effects and minimal efficacy.
한편, 안지오텐신 전환효소 2(Angiotensin converting enzyme 2, ACE2)는 체내 수분과 혈압을 조절하는 레닌-안지오텐신-알도스테론계(Renin-angiotensin-aldosterone system, RAAS)에서 중요한 역할을 담당한다. Meanwhile, Angiotensin converting enzyme 2 (ACE2) plays an important role in the Renin-angiotensin-aldosterone system (RAAS), which regulates body moisture and blood pressure.
레닌-안지오텐신-알도스테론계(RAAS)에서 레닌에 의해 안지오텐시노겐이 안지오텐신 I으로 되고, 안지오텐시전환효소 (angiotensin converting enzyme, ACE)가 안지오텐신 I을 안지오텐신 II로 전환시킨다. 안지오텐신 II는 혈관 내 염증반응, 죽상동맹경화증 촉진 등 심혈관계에 직접적으로 '악영향'을 끼친다. 그런데, 체내의 안지오텐신 II는 상기 ACE2에 의해 안지오텐신(1-7)로 전환되며 그 결과 항상성을 유지할 수 있게 된다. 따라서, ACE2는 체내 항상성 유지에 중요한 효소라 할 수 있다.In the renin-angiotensin-aldosterone system (RAAS), renin converts angiotensinogen into angiotensin I, and angiotensin converting enzyme (ACE) converts angiotensin I into angiotensin II. Angiotensin II has a direct ‘adverse effect’ on the cardiovascular system, including inflammatory reactions within blood vessels and promoting atherosclerosis. However, angiotensin II in the body is converted to angiotensin (1-7) by ACE2, and as a result, homeostasis can be maintained. Therefore, ACE2 can be said to be an important enzyme in maintaining body homeostasis.
ACE2는 막관통부위를 가지고 있으며 이를 이용하여 세포막에 함입된 채로 체내에 존재한다. 상기의 특성으로 인해 최근 수용성 ACE2(soluble ACE2, sACE2)를 이용하여 바이러스의 감염을 예방하거나, 감염된 바이러스의 증식을 억제하는 등 항바이러스제로서의 가능성 대한 연구가 많이 보고되고 있으며, 다양한 유전자 재조합을 통한 수용성 ACE2(recombinant soluble ACE2, rsACE2)도 개발되고 있다. 그럼에도 불구하고 수용성 ACE2를 이용한 항바이러스제는 낮은 in vivo 항바이러스 효능으로 인해 제약이 있는 상황이다. ACE2 has a transmembrane site and exists in the body by being incorporated into the cell membrane. Due to the above characteristics, many studies have recently been reported on the possibility of using soluble ACE2 (soluble ACE2, sACE2) as an antiviral agent, such as preventing viral infection or suppressing the proliferation of infected viruses. ACE2 (recombinant soluble ACE2, rsACE2) is also being developed. Nevertheless, antiviral drugs using soluble ACE2 have limitations due to low in vivo antiviral efficacy.
본 발명에서는 기존 나노디스크 구조체 내 막구조화 단백질 (Membrane scaffold protein, MSP)이 열에 대한 안정성과 체내 단백질분해효소로부터 저항성이 낮은 점을 고려하여 이를 양친매성 폴리머로 대체함으로써 구조체의 안정성을 개선하고자 한다. 또한, 이를 통해, 항바이러스 효능이 우수한 바이러스 감염증 예방 또는 치료용 약학 조성물을 제공하고자 한다.In the present invention, considering that the membrane scaffold protein (MSP) in the existing nanodisk structure has low stability to heat and low resistance to proteolytic enzymes in the body, we seek to improve the stability of the structure by replacing it with an amphipathic polymer. In addition, through this, it is intended to provide a pharmaceutical composition for preventing or treating viral infections with excellent antiviral efficacy.
본 발명은 인지질을 사용하여 형성된 납작한 원반 형태의 이중층 구조로서, 친수성기는 외부로 배향되고, 소수성기는 내부로 배향되어 있는 지질 이중층 (lipid bilayer); 상기 지질 이중층의, '소수성기가 외부로 노출되어 있는 측면'을 소수성 결합으로 둘러싸는 양친매성 폴리머 (amphipathic polymer); 및 상기 지질 이중층 내부와 소수성 결합되는 안지오텐진 전환효소 2 (Angiotensin converting enzyme 2, ACE2)를 포함하는 것을 특징으로 하는 폴리머 나노디스크를 제공한다.The present invention is a flat disk-shaped bilayer structure formed using phospholipids, a lipid bilayer in which the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside; an amphipathic polymer that surrounds the ‘side where the hydrophobic group is exposed to the outside’ of the lipid bilayer with a hydrophobic bond; and angiotensin converting enzyme 2 (ACE2) hydrophobically bound to the inside of the lipid bilayer.
본 발명의 폴리머 나노디스크에 있어서, 상기 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)는 바람직하게 트랜스멤브레인 도메인 (transmembrane domain)이 지질 이중층의 소수성 부위에 결합되어 있는 것이 좋다.In the polymer nanodisk of the present invention, the transmembrane domain of the angiotensin converting enzyme 2 (ACE2) is preferably bound to a hydrophobic portion of the lipid bilayer.
본 발명의 폴리머 나노디스크에 있어서, 상기 인지질은 일예로, 포스파티딜콜린(phosphatidylcholine), 포스파티딜세린(phosphatidylserine), 포스파티딜에탄올아민(phophatidylethalolamine), 포스파티딜글리세롤(phophatidylglycerol) 및 포스파티딜이노시톨(phophatidylinositol) 중 선택되는 하나 이상일 수 있는데, 바람직하게는, DMPC(1,2-dimyristoyl-sn-glycero-3-phosphocholine), DPPC(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DSPC(1,2-distearoyl-sn-glycero-3-phosphocholine), POPC(l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPS(1,2-dioleoyl-sn-glycero-3-phospho-L-serine), 및 POPE(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) 중 선택되는 어느 하나 이상을 포함하는 것이 좋다.In the polymer nanodisc of the present invention, the phospholipid may be, for example, one or more selected from phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phophatidylglycerol, and phosphatidylinositol. Preferably, DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DSPC (1,2-distearoyl-sn- glycero-3-phosphocholine), POPC (l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine), and POPE ( It is recommended to include at least one selected from 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine).
본 발명의 폴리머 나노디스크에 있어서, 상기 양친매성 폴리머 (amphipathic polymer)는 바람직하게 스티렌-말레산(Styrene-Maleic Acid, SMA), 디-이소부틸렌-말레산(Di-IsoButylene-Maleic Acid, DIBMA), 스티렌-말레이미드(Styrene-Maleimide, SMI), 폴리메타크릴레이트(Polymethyl Methacrylate, PMA) 중 선택되는 어느 하나 이상인 것이 좋다.In the polymer nanodisk of the present invention, the amphipathic polymer is preferably Styrene-Maleic Acid (SMA) or Di-IsoButylene-Maleic Acid (DIBMA). ), Styrene-Maleimide (SMI), and polymethyl methacrylate (PMA).
본 발명의 폴리머 나노디스크에 있어서, 상기 안지오텐신 전환효소 2는 수용성 안지오텐신 전환효소 2일 수 있다.In the polymer nanodisc of the present invention, the angiotensin converting enzyme 2 may be water-soluble angiotensin converting enzyme 2.
한편, 본 발명은 상기 본 발명의 폴리머 나노디스크를 포함하는 것을 특징으로 하는 바이러스 감염증 예방 또는 치료용 약학조성물을 제공한다.Meanwhile, the present invention provides a pharmaceutical composition for preventing or treating viral infections, comprising the polymer nanodisc of the present invention.
본 발명의 지질 이중층, 양친매성 폴리머 및 안지오텐신 전환효소 2를 포함하는 폴리머 나노디스크는 항바이러스 효능이 우수하다. 이에 본 발명의 폴리머 나노디스크는 바이러스 감염증 예방 또는 치료용 약학 조성물로 사용할 수 있다.The polymer nanodisc containing the lipid bilayer, amphiphilic polymer, and angiotensin converting enzyme 2 of the present invention has excellent antiviral efficacy. Accordingly, the polymer nanodisc of the present invention can be used as a pharmaceutical composition for preventing or treating viral infections.
또한, 본 발명의 폴리머 나노디스크는 기존 나노디스크에 사용하던 막구조화 단백질 (Membrane scaffold protein, MSP)을 폴리머 성분으로 대체하여, 구조 안정성이 우수하면서도, 더욱 경제적인 생산이 가능하다.In addition, the polymer nanodisc of the present invention replaces the membrane scaffold protein (MSP) used in existing nanodiscs with a polymer component, enabling excellent structural stability and more economical production.
도 1은 본 발명 폴리머 나노디스크의 구조를 개략적으로 보여준다.Figure 1 schematically shows the structure of the polymer nanodisk of the present invention.
도 2는 본 발명 폴리머 나노디스크를 포함하는 농축액을 정제하기 위해 크기배제 크로마토그래피를 실시한 결과이다.Figure 2 shows the results of size exclusion chromatography to purify a concentrate containing the polymer nanodisc of the present invention.
도 3은 기존의 막구조화 단백질 (Membrane scaffold protein, MSP)을 포함하는 나노디스크 (MSPNDA)와 막구조화 단백질 (Membrane scaffold protein, MSP)을 폴리머 성분으로 대체한 본 발명의 폴리머 나노디스크 (SMANDA)의 항바이러스 효능을 비교한 결과이다.Figure 3 shows a nanodisk (MSPNDA) containing an existing membrane scaffold protein (MSP) and a polymer nanodisk (SMANDA) of the present invention in which the membrane scaffold protein (MSP) is replaced with a polymer component. This is the result of comparing antiviral efficacy.
본 발명은 인지질을 사용하여 형성된 납작한 원반 형태의 이중층 구조로서, 친수성기는 외부로 배향되고, 소수성기는 내부로 배향되어 있는 지질 이중층 (lipid bilayer); 상기 지질 이중층의, '소수성기가 외부로 노출되어 있는 측면'을 소수성 결합으로 둘러싸는 양친매성 폴리머 (amphipathic polymer); 및 상기 지질 이중층 내부와 소수성 결합되는 안지오텐진 전환효소 2 (Angiotensin converting enzyme 2, ACE2)를 포함하는 것을 특징으로 하는 폴리머 나노디스크를 제공한다.The present invention is a flat disk-shaped bilayer structure formed using phospholipids, a lipid bilayer in which the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside; an amphipathic polymer that surrounds the ‘side where the hydrophobic group is exposed to the outside’ of the lipid bilayer with a hydrophobic bond; and angiotensin converting enzyme 2 (ACE2) hydrophobically bound to the inside of the lipid bilayer.
본 발명자는 대한민국 등록특허 제10-2438720호, 제10-2438721호를 통해 막구조화 단백질 (Membrane scaffold protein, MSP)과 바이러스 수용체로 ACE2를 사용하여 항바이러스 효능이 우수한 나노디스크를 개발한 바가 있다. 이후, 상기 나노디스크를 보다 간편하고 경제성 있게 제조할 수 있는 기술을 개발하던 중, 본 발명을 통해 나노디스크 내 막구조화 단백질(MSP)을 양친매성 폴리머 성분으로 대체하여 나노디스크를 제조할 수 있는 기술을 개발하였다. 이렇게 개발한 본 발명의 나노디스크는 기존에 MSP 및 ACE2를 사용하여 제조된 대한민국 등록특허 10-2438720의 나노디스크처럼 항바이러스 활성을 나타냈다. 특히나 양친매성 폴리머로 스티렌과 말레산을 2:1의 중량비율로 사용하여 MSP를 대체하여 사용할 경우, MSP로 만든 나노디스크와 거의 비슷한 항바이러스 효능을 보임을 확인할 수 있었다. Through Korean Patent Nos. 10-2438720 and 10-2438721, the present inventor has developed nanodiscs with excellent antiviral efficacy using membrane scaffold protein (MSP) and ACE2 as a viral receptor. Later, while developing a technology to manufacture the nanodisk more simply and economically, the present invention developed a technology to manufacture nanodiscs by replacing the membrane structural protein (MSP) in the nanodisk with an amphipathic polymer component. was developed. The nanodisc of the present invention developed in this way showed antiviral activity like the nanodisc of Korean Patent No. 10-2438720, which was previously manufactured using MSP and ACE2. In particular, when styrene and maleic acid were used as an amphiphilic polymer in a weight ratio of 2:1 to replace MSP, it was confirmed that the antiviral efficacy was almost similar to that of nanodiscs made with MSP.
MSP를 양친매성 폴리머로 대체하여 제조된 본 발명의 폴리머 나노디스크는 단백질을 폴리머 성분으로 대체하였기 때문에 열안정성이 높고, 제조단가가 낮아 매우 경제적이고 제조 공정을 단순화 할 수 있는 큰 장점이 있다. The polymer nanodisc of the present invention, manufactured by replacing MSP with an amphiphilic polymer, has the great advantage of being very economical and simplifying the manufacturing process due to its high thermal stability and low manufacturing cost because the protein is replaced with a polymer component.
한편, 본 발명의 지질 이중층 (lipid bilayer)은 인지질을 사용하여 형성된 납작한 원반 형태의 이중층 구조로서, 친수성기는 외부로 배향되고, 소수성기는 내부로 배향되어 있는 것에 특징이 있다. 즉, 본 발명의 지질 이중층 (lipid bilayer)은 인지질의 친수성 부위뿐만 아니라, 소수성 부위도 측면을 통해 외부에 노출된 부분을 갖는 원반 형태 (도 1 참조)라는 점에서, 친수성 또는 소수성 부위 중 선택적으로 하나만이 외부에 노출되는 구(sphere) 형태의 리포좀(liposome)과 구조상 차이가 있다.Meanwhile, the lipid bilayer of the present invention is a flat disk-shaped bilayer structure formed using phospholipids, and is characterized in that the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside. That is, the lipid bilayer of the present invention is in the form of a disk (see Figure 1) with not only the hydrophilic portion of the phospholipid, but also the hydrophobic portion exposed to the outside through the side, so that it can be selectively selected between the hydrophilic or hydrophobic portion. Only one is structurally different from the sphere-shaped liposome exposed to the outside.
본 발명의 인지질은 예로서, 포스파티딜콜린(phosphatidylcholine), 포스파티딜글리세롤(phosphatidylglycerol), 포스파티딜에탄올아민(phosphatidylethanolamine), 포스파티딜세린(phosphatidylserine) 및 포스파티딜이노시톨(phophatidylinositol)로 이루 어진 군에서 선택된 1 종 이상일 수 있다.For example, the phospholipid of the present invention may be one or more selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol.
상기 포스파티딜콜린(phosphatidylcholine)은 일 예로 DOPC(1,2-Dioleoyl-sn-glycero-3-phosphocholine), DLPC(1,2-Dilauroyl-sn-glycero-3-phosphocholine), DMPC(1,2-Dimyristoyl-sn-glycero-3-phosphocholine), DPPC(1,2-Dipalmitoyl-sn-glycero-3-phosphocholine), POPC(1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), C13PC, DDPC(1,2-Didecanoyl-sn-glycero-3-phosphocholine), DSPC(1,2-Distearoyl-sn-glycero-3-phosphocholine), DEPC(1,2-Dierucoyl-sn-glycero-3-phosphocholine), DLOPC(1,2-Dilinoleoyl-sn-glycero-3-phosphocholine), EPC(Egg phosphatidylcholine), MSPC( 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine), PMPC(1-Palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine), PSPC(1-Palmitoyl-2- stearoyl-sn-glycero-3-phosphocholine), SMPC(1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine) 또는 SPPC(1-Stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine)일 수 있다. The phosphatidylcholine is, for example, DOPC (1,2-Dioleoyl-sn-glycero-3-phosphocholine), DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine), DMPC (1,2-Dimyristoyl- sn-glycero-3-phosphocholine), DPPC (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine), POPC (1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), C13PC, DDPC (1 ,2-Didecanoyl-sn-glycero-3-phosphocholine), DSPC(1,2-Distearoyl-sn-glycero-3-phosphocholine), DEPC(1,2-Dierucoyl-sn-glycero-3-phosphocholine), DLOPC( 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine), EPC (Egg phosphatidylcholine), MSPC (1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine), PMPC (1-Palmitoyl-2-myristoyl- sn-glycero-3-phosphocholine), PSPC (1-Palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine), SMPC (1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine) or SPPC (1 -Stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine).
또한, 상기 포스파티딜글리세롤은 일 예로 DMPG(1,2-Dimyristoyl-sn-glycero-3[Phospho-rac-(1-glycerol)], DPPG(1,2-Dipalmitoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DSPG(1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)), POPG(1-Palmitoyl-2-oleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DEPG(1,2-Dierucoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DLPG(1,2-Dilauroyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DOPG(1,2-Dioleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) 또는 DSPG(1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)])일 수 있고, 상기 포스파티딜에탄올아민은, DMPE(1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine), DPPE(1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine), DSPE(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine), DOPE(1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), DEPE(1,2-Dierucoyl-sn-glycero-3-phosphoethanolamine), DLPE(1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine) 또는 POPE(1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine), 상기 포스파티딜세린은, DOPS(1,2-Dioleoyl-sn-glycero-3-phosphoserine), DLPS(1,2-Dilauroyl-sn-glycero-3-phosphoserine), DMPS(1,2-Dimyristoyl-sn-glycero-3-phosphoserine), DPPS(1,2-Dipalmitoyl-sn-glycero-3-phosphoserine), DSPS(1,2-Distearoyl-sn-glycero-3-phosphoserine) 또는 POPS, 상기 포스파티딜이노시톨(phophatidylinositol)은 포스파티딜이노시톨-4-인산(phosphatidylinositol-4-phosphate), 포스파티딜이노시톨-4,5-비스인산(phosphatidylinositol-4,5-bisphosphate), 포스파티딜이노시톨-3,4,5-트리스인산(phosphatidylinositol-4,5-bisphosphate)일 수 있다.In addition, the phosphatidyl glycerol is, for example, DMPG (1,2-Dimyristoyl-sn-glycero-3[Phospho-rac-(1-glycerol)], DPPG (1,2-Dipalmitoyl-sn-glycero-3[Phospho-rac) -(1-glycerol)]), DSPG(1,2-Distearoyl-sn-glycero-3[Phospho-rac-(1-glycerol)), POPG(1-Palmitoyl-2-oleoyl-sn-glycero-3[ Phospho-rac-(1-glycerol)]), DEPG(1,2-Dierucoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]), DLPG(1,2-Dilauroyl-sn-glycero- 3[Phospho-rac-(1-glycerol)]), DOPG(1,2-Dioleoyl-sn-glycero-3[Phospho-rac-(1-glycerol)]) or DSPG(1,2-Distearoyl-sn- It may be glycero-3[Phospho-rac-(1-glycerol)]), and the phosphatidylethanolamine may be DMPE (1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine), DPPE (1,2-Dipalmitoyl- sn-glycero-3-phosphoethanolamine), DSPE(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine), DOPE(1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine), DEPE(1,2-Dierucoyl -sn-glycero-3-phosphoethanolamine), DLPE (1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine) or POPE (1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine), the phosphatidylserine , DOPS(1,2-Dioleoyl-sn-glycero-3-phosphoserine), DLPS(1,2-Dilauroyl-sn-glycero-3-phosphoserine), DMPS(1,2-Dimyristoyl-sn-glycero-3-phosphoserine) ), DPPS (1,2-Dipalmitoyl-sn-glycero-3-phosphoserine), DSPS (1,2-Distearoyl-sn-glycero-3-phosphoserine) or POPS, the phosphatidylinositol is phosphatidylinositol-4- It can be phosphatidylinositol-4-phosphate, phosphatidylinositol-4,5-bisphosphate, or phosphatidylinositol-3,4,5-trisphosphate. there is.
본 발명의 양친매성 폴리머 (amphipathic polymer)는 양친매성을 가지고 있어서 소수성 꼬리 (acyl tail)가 물에 직접 노출되는 것을 방지하는 역할을 한다. 이 양친매성 폴리머가 일정 비율로 존재하게 되면 지질이중막을 형성한 인지질의 중간층(2겹의 소수성 아실 꼬리(acyl tail))을 폴리머가 감싸게 된다. 결과적으로 디스크 형태의 지질이중막 모양이 수용액상에서 안정화된다. 이때, 인지질:폴리머 비율에 따라서 지질이중막 디스크의 크기가 결정된다.The amphipathic polymer of the present invention has amphipathic properties and thus serves to prevent the hydrophobic tail (acyl tail) from being directly exposed to water. When this amphiphilic polymer is present in a certain ratio, the polymer wraps around the middle layer of phospholipids (two-layer hydrophobic acyl tails) forming a lipid bilayer. As a result, the disk-shaped lipid bilayer shape is stabilized in aqueous solution. At this time, the size of the lipid bilayer disk is determined depending on the phospholipid:polymer ratio.
한편, 본 발명의 양친매성 폴리머 (amphipathic polymer)는 바람직하게 스티렌-말레산(Styrene-Maleic Acid, SMA), 디-이소부틸렌-말레산(Di-IsoButylene-Maleic Acid, DIBMA), 스티렌-말레이미드(Styrene-Maleimide, SMI), 폴리메타크릴레이트(Polymethyl Methacrylate, PMA) 중 선택되는 어느 하나 이상인 것이 좋다.Meanwhile, the amphipathic polymer of the present invention is preferably styrene-maleic acid (SMA), di-Isobutylene-maleic acid (DIBMA), or styrene-maleic acid. It is better to use at least one selected from styrene-maleimide (SMI) and polymethyl methacrylate (PMA).
상기 SMA는 스티렌(Styrene)과 말레산(maleic acid)를 중합시킨 코폴리머인 것으로, 당업계에 널리 알려진 중합방법에 의해 중합될 수 있다. 이때, SMA는 추가적으로 에탄올아민, 에틸렌디아민, 4차 암모니움, 설프하이드릴 등으로 수식될 수 있다. The SMA is a copolymer obtained by polymerizing styrene and maleic acid, and can be polymerized using a polymerization method widely known in the art. At this time, SMA can be additionally modified with ethanolamine, ethylenediamine, quaternary ammonium, sulfhydryl, etc.
한편, 본 발명의 폴리머 나노디스크는 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)가 지질 이중층에 결합된 것에 특징이 있다 (도 1 참조). 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)는 C-말단에 소수성을 띄는 트랜스멤브레인 도메인 (transmembrane domain)을 가지고 있는데, 이 부위가 지질 이중층 (lipid bilayer)의 소수성 부위와 만나 소수성 결합되는 것이다.Meanwhile, the polymer nanodisc of the present invention is characterized in that Angiotensin converting enzyme 2 (ACE2) is bound to a lipid bilayer (see Figure 1). Angiotensin converting enzyme 2 (ACE2) has a hydrophobic transmembrane domain at the C-terminus, and this region meets the hydrophobic region of the lipid bilayer and forms a hydrophobic bond.
이때, 상기 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)는 수용성 안지오텐신 전환효소 2일 수도 있다. 기존 안지오텐신 전환효소 2 (ACE2)에는 막관통부위가 있으며, 이를 이용하여 세포막에 함입된 채로 존재한다. 최근 안지오텐신 전환효소 2 (ACE2)의 바이러스와의 결합능이 보고됨에 따라, 이를 이용하여 바이러스의 감염을 예방하거나 감염된 바이러스의 증식을 억제하는 등의 항바이러스제로서의 가능성 대한 연구가 많이 보고되고 있으며, 활용성 및 기능성을 더욱 향상시키기 위해 다양한 유전자 재조합을 통한 수용성 ACE2 (recombinant soluble ACE2, rsACE2)가 개발되고 있다. 본 발명에서 이렇게 개발된 수용성 ACE2를 사용할 수도 있는 것이다. At this time, the angiotensin converting enzyme 2 (ACE2) may be water-soluble angiotensin converting enzyme 2. Existing angiotensin-converting enzyme 2 (ACE2) has a transmembrane site and exists embedded in the cell membrane using this site. Recently, as the ability of angiotensin-converting enzyme 2 (ACE2) to bind to viruses has been reported, many studies have been reported on its potential as an antiviral agent that uses it to prevent viral infection or inhibit the proliferation of infected viruses. And to further improve functionality, soluble ACE2 (recombinant soluble ACE2, rsACE2) is being developed through various genetic recombination. In the present invention, the water-soluble ACE2 developed in this way can also be used.
한편, 본 발명은 상기 본 발명의 나노디스크(nanodisc)를 포함하는 것을 특징으로 하는 바이러스 감염증 예방 또는 치료용 약학 조성물을 제공한다.Meanwhile, the present invention provides a pharmaceutical composition for preventing or treating viral infections, comprising the nanodisc of the present invention.
본 발명에서 "바이러스 감염증"이란, 일 예로서, 버니아비리데 과의 바이러스의 감염에 의하여 발병되는 신증후근성출혈열(유행성출혈열); 코로나비리데 과의 바이러스의 감염에 의하여 발병되는 코감기 등 호흡기 질환 또는 코로나바이러스 감염증; 플라비비리데 과의 바이러스의 감염에 의하여 발병되는 C형 간염; 헤파드나비리데 과의 바이러스의 감염에 의하여 발병되는 B형 간염; 헤르페스비리데 과의 바이러스의 감염에 의하여 발병되는 대상포진; 오르소믹소비리데 과의 바이러스의 감염에 의하여 발병되는 독감 또는 인플루엔자 바이러스 감염증; 폭스비리데 과의 바이러스의 감염에 의하여 발병되는 천연두; 랍도비리데 과의 바이러스의 감염에 의하여 발병되는 광견병 또는 수포성 구내염; 레트로비리데과의 바이러스의 감염에 의하여 발병되는 후천성 면역결핍증 등이 될 수 있고, 다른 예로서, 오르소믹소비리데과에 속하는 인플루엔자 바이러스의 감염에 의하여 발병되는 독감 또는 인플루엔자 바이러스 감염증이 될 수 있다. 다만, 바람직하게는 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)와 결합할 수 있는 스파이크 단백질을 갖는 코로나 바이러스 감염증인 것이 좋다. SARS-CoV-2를 포함한 여러 코로나바이러스는 안지오텐신 전환효소 2를 수용체로 이용하며, 이에 안지오텐신 전환효소 2와 결합능이 있는 것으로 알려져 있다. In the present invention, “viral infection” includes, for example, renal syndrome hemorrhagic fever (epidemic hemorrhagic fever) caused by infection with a virus of the Verniaviridae family; Respiratory diseases such as nasal colds or coronavirus infections caused by infection with viruses of the Coronaviridae family; Hepatitis C caused by infection with viruses of the Flaviviridae family; Hepatitis B caused by infection with viruses of the Hepadnaviridae family; Shingles caused by infection with viruses of the Herpesviridae family; Flu or influenza virus infection caused by infection with a virus of the Orthomyxoviridae family; Smallpox caused by infection with viruses of the Poxviridae family; Rabies or vesicular stomatitis caused by infection with viruses of the Rhabdoviridae family; It can be an acquired immunodeficiency syndrome caused by infection with a virus of the retroviridae family, and as another example, it can be a flu or influenza virus infection caused by infection by an influenza virus belonging to the orthomyxoviridae family. However, preferably it is a coronavirus infection that has a spike protein that can bind to angiotensin converting enzyme 2 (ACE2). Several coronaviruses, including SARS-CoV-2, use angiotensin-converting enzyme 2 as a receptor, and are known to have the ability to bind to angiotensin-converting enzyme 2.
본 발명의 약학 조성물은 유효성분인 상기 조성물 외에 약학으로 허용되는 담체를 포함할 수 있다.The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the composition as an active ingredient.
본 발명의 약학 조성물에 포함되는 약학으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in preparation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, and calcium silicate. , microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, etc. no.
본 발명의 약학 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 예컨대 척추강 내 투여, 정맥내 투여, 피하 투여, 피내 투여, 근육내 투여, 복강내 투여, 흉골 내 투여, 종양 내 투여, 비내 투여, 뇌내 투여, 두개골 내 투여, 폐내 투여 및 직장내 투여 등으로 투여할 수 있으나 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention can be administered orally or parenterally, for example, intrathecal administration, intravenous administration, subcutaneous administration, intradermal administration, intramuscular administration, intraperitoneal administration, intrasternal administration, intratumoral administration, intranasal administration, It can be administered by intracerebral administration, intracranial administration, intrapulmonary administration, and intrarectal administration, but is not limited thereto.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량(약학 유효량)을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학 조성물의 1일 투여량은 0.0001-100 ㎎/㎏이다. The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is usually A skilled doctor can easily determine and prescribe an effective dosage (pharmaceutically effective amount) for desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-100 mg/kg.
본 발명의 용어 "약학 유효량"은 상술한 질환을 예방 또는 치료하는 데 충분한 양을 의미한다.The term “pharmaceutically effective amount” of the present invention means an amount sufficient to prevent or treat the above-mentioned disease.
본 발명의 용어 "예방"은 질환 또는 질환 상태의 방지 또는 보호적인 치료를 의미한다. 본 발명의 용어 "치료"는 질환 상태의 감소, 억제, 진정 또는 근절을 의미한다.As used herein, the term “prophylaxis” refers to the prevention or protective treatment of a disease or disease state. As used herein, the term “treatment” means reducing, suppressing, alleviating or eradicating a disease state.
본 발명의 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 내복약, 주사제 등 다양하게 제조될 수 있고, 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 산제, 좌제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using pharmaceutically acceptable carriers and/or excipients according to a method that can be easily performed by those skilled in the art. It can be manufactured by placing it in a multi-capacity container. At this time, the dosage form can be manufactured in a variety of ways, such as oral medicine or injection, and can be in the form of a solution, suspension or emulsion in oil or aqueous medium, or in the form of extract, powder, suppository, powder, granule, tablet or capsule, and may be in the form of a dispersant or stabilizer. Additional topics may be included.
이하, 본 발명의 내용을 하기 실시예를 통하여 보다 상세하게 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고 그와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the contents of the present invention will be described in more detail through the following examples. However, the scope of the present invention is not limited to the following examples and includes modifications of the technical idea equivalent thereto.
[실시예 1: ACE2가 포함된 본 발명의 폴리머 나노디스크 제작][Example 1: Production of polymer nanodisc of the present invention containing ACE2]
1-1) ACE2 막단백질 정제1-1) ACE2 membrane protein purification
단백질의 정제를 위해 HEK293(Human embryonic kidney 293) 수용성 부유세포를 37℃, 120 rpm, 8% CO2의 조건하로 배양하여, 1.1×106 cells/mL, 180 mL를 준비하였다. 인간에서 유래한 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2) 유전자 (서열번호 1) 함유 플라스미드 250 μg과 PEI(poly ethylenimine) 750 μg를 배지 20 mL에 혼합한 후, 상기 준비한 180 mL의 세포액과 혼합하여 형질주입(Transfection) 하였다. For protein purification, HEK293 (Human embryonic kidney 293) soluble suspension cells were cultured at 37°C, 120 rpm, and 8% CO 2 to prepare 1.1×10 6 cells/mL, 180 mL. After mixing 250 μg of a plasmid containing the human-derived Angiotensin converting enzyme 2 (ACE2) gene (SEQ ID NO: 1) and 750 μg of PEI (poly ethylenimine) in 20 mL of medium, 180 mL of cell fluid prepared above and They were mixed and transfected.
이후 37℃, 120 rpm, 8% CO2 조건의 인큐베이터에서 세포를 72시간 배양한 후 8000 g에서 10분간 원심분리하여 배지를 제거하고 세포만 얻어내었다. Afterwards, the cells were cultured in an incubator at 37°C, 120 rpm, and 8% CO 2 for 72 hours, and then centrifuged at 8000 g for 10 minutes to remove the medium and obtain only the cells.
상기 세포에 1% DDM이 포함된 Tris 완충액을 사용하여 세포를 재부유시키고, 초고속 원심분리기를 이용해 막단백질을 분리 한 후, Ni-NTA 아가로스 비드를 이용해 정제하였다. 이후 0.1% DDM과 저농도의 이미다졸(imidazole)이 포함된 완충액을 이용하여 비드에 결합하지 못한 물질들을 제거하였고, 고농도의 이미다졸을 이용해 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2) (서열번호 2)를 얻어내었다. The cells were resuspended using Tris buffer containing 1% DDM, membrane proteins were separated using an ultra-high-speed centrifuge, and purified using Ni-NTA agarose beads. Afterwards, substances that failed to bind to the beads were removed using a buffer containing 0.1% DDM and a low concentration of imidazole, and angiotensin converting enzyme 2 (ACE2) (SEQ ID NO. 2) was obtained.
한편, 수용성 안지오텐신 전환효소 2 (Soluble ACE2; sACE2)는 상기의 방법에서 수용성 ACE2 유전자 (서열번호 3) 함유 플라스미드를 이용하여 형질주입(Transfection)을 진행하였으며 37℃, 120 rpm, 8% CO2 조건의 인큐베이터에서 세포를 72시간 배양한 후 8000×g에서 10분간 원심분리하여 세포를 제거하고 상층액을 Ni-NTA 아가로스 비드를 이용해 정제하였다. 이후 저농도의 이미다졸이 포함된 완충액을 이용하여 비드에 결합하지 못한 물질들을 제거하였고, 고농도의 이미다졸을 이용해 수용성 안지오텐신 전환효소 2 (Soluble ACE2; sACE2) (서열번호 4)를 얻어내었다.Meanwhile, soluble angiotensin converting enzyme 2 (Soluble ACE2; sACE2) was transfected using a plasmid containing the soluble ACE2 gene (SEQ ID NO: 3) in the above method, under the conditions of 37°C, 120 rpm, and 8% CO 2. After culturing the cells in an incubator for 72 hours, the cells were removed by centrifugation at 8000 × g for 10 minutes, and the supernatant was purified using Ni-NTA agarose beads. Afterwards, substances that failed to bind to the beads were removed using a buffer containing a low concentration of imidazole, and water-soluble angiotensin converting enzyme 2 (Soluble ACE2; sACE2) (SEQ ID NO: 4) was obtained using a high concentration of imidazole.
1-2) ACE2가 포함된 본 발명의 폴리머 나노디스크 (SMANDA)의 제작 및 정제1-2) Production and purification of polymer nanodisc (SMANDA) of the present invention containing ACE2
본 발명의 폴리머 나노디스크를 제작하기 위해 양친매성 폴리머로써 SMA(Styrene-Maleic Acid) 중 Styrene : Maleic acid를 2:1 또는 3:1의 몰비율로 중합된 두 종류의 폴리머를 사용하여 제조하였다. 구성 지질은 POPC(l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)를 사용하였다. 폴리머와 지질은 1:2의 중량 비율로 사용하였다.In order to manufacture the polymer nanodisc of the present invention, two types of polymers were used as amphiphilic polymers, in which Styrene:Maleic acid of SMA (Styrene-Maleic Acid) was polymerized at a molar ratio of 2:1 or 3:1. POPC (l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) was used as the constituent lipid. Polymer and lipid were used at a weight ratio of 1:2.
본 발명의 폴리머 나노디스크의 제조방법은 구체적으로 다음과 같다.The manufacturing method of the polymer nanodisk of the present invention is specifically as follows.
먼저 고체 가루 형태의 지질을 유기용매에 녹인 후, 지질을 유리관에서 혼합한 뒤 질소 가스와 진공관을 이용해 유기용매를 완전히 기화시켜 필름 형태의 지질만 남겼다. 수화 버퍼(10 mM HEPES, 150 mM NaCl; pH 7.4)를 이용해 필름 형태의 지질을 5분 이상 충분히 녹인 후, 액체 질소와 50℃의 물을 이용해 동결과 융해과정을 5회 이상 수행하여 리포좀을 생성하였다. 이후, 압출장치에 100 nm 크기를 갖는 막을 끼워 넣고, 압력을 이용해 막 좌우로 리포좀 용액을 반복 통과시켜 리포좀의 직경이 100 nm 이하로 조절한다. 혼합액에 tritonX-100 시약을 2 mM의 농도가 되도록 섞어준 후, 1 시간동안 반응시킨다. 안지오텐신 전환효소 2와 지질의 무게비율이 1:120 이 되도록 정제한 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)를 첨가한다. 30 분 동안 실온에서 약하게 섞는 과정을 거친 후, 비드를 80 mg/ml 농도로 첨가하여 2 시간동안 실온에서 반응시키면서 tritonX-100을 제거한다. 깨끗한 비드를 2회 반복 처리한 후, 원심기를 통해 분리하여 비드를 제거한다. 마지막으로 각 폴리머(SMA 2:1, SMA 3:1 두 종류)와 지질의 w/w 비율이 1:2가 되도록 폴리머를 첨가한 뒤 액체 질소와 50 ℃의 소니케이터를 이용해 동결 및 음파처리 과정을 3회 수행하였다. 이를 통해 폴리머가 리포좀을 파고들면서 물 분자가 끼어들어 지질층 사이에 구멍(pore)을 형성하게 되고 최종적으로 나노디스크 구조가 형성시킬 수 있었다. 나노디스크를 형성하지 못한 폴리머와 직경이 큰 리포좀을 제거하기 위해 초고속 원심분리 여과(Ultracentrifugal filtration)를 수행하여 농축액을 얻었다. 이후, 나노디스크의 농축액을 크기배제 크로마토그래피(도 2)를 통해 크기에 따라 정제하고 얻어진 샘플을 농축하여 ACE2가 포함된 폴리머 나노디스크 (SMANDA) 농축액을 얻을 수 있었다.First, lipids in the form of solid powder were dissolved in an organic solvent, the lipids were mixed in a glass tube, and the organic solvent was completely vaporized using nitrogen gas and a vacuum tube, leaving only the lipids in the form of a film. After sufficiently dissolving the film-shaped lipids for more than 5 minutes using hydration buffer (10mM HEPES, 150mM NaCl; pH 7.4), freeze and thaw processes were performed more than 5 times using liquid nitrogen and water at 50°C to generate liposomes. did. Afterwards, a membrane with a size of 100 nm is inserted into the extrusion device, and the liposome solution is repeatedly passed to the left and right of the membrane using pressure to adjust the liposome diameter to 100 nm or less. After mixing the tritonX-100 reagent to a concentration of 2mM, react for 1 hour. Add purified Angiotensin converting enzyme 2 (ACE2) so that the weight ratio of Angiotensin converting enzyme 2 to lipid is 1:120. After gentle mixing at room temperature for 30 minutes, beads were added at a concentration of 80 mg/ml and reacted at room temperature for 2 hours to remove tritonX-100. After processing the clean beads twice, the beads are separated by centrifugation. Finally, the polymers were added so that the w/w ratio of each polymer (two types of SMA 2:1 and SMA 3:1) and lipid was 1:2, and then frozen and sonicated using liquid nitrogen and a sonicator at 50°C. The process was performed three times. Through this, as the polymer penetrates the liposome, water molecules enter and form pores between the lipid layers, ultimately forming a nanodisk structure. Ultracentrifugal filtration was performed to remove polymers that did not form nanodisks and liposomes with large diameters to obtain a concentrate. Afterwards, the nanodisc concentrate was purified according to size through size exclusion chromatography (Figure 2), and the obtained sample was concentrated to obtain a polymer nanodisc (SMANDA) concentrate containing ACE2.
한편, DLS를 통해 나노디스크의 직경을 측정한 결과, SMA(2:1)를 첨가하였을 때의 평균 직경이 13.31 nm로 나타났고 SMA(3:1)를 첨가하였을 때의 평균 직경은 9.71 nm로 나타났다.Meanwhile, as a result of measuring the diameter of the nanodisk through DLS, the average diameter when SMA (2:1) was added was found to be 13.31 nm, and when SMA (3:1) was added, the average diameter was 9.71 nm. appear.
[실시예 2: ACE2가 포함된 본 발명 폴리머 나노디스크의 항바이러스 효능 확인 실험][Example 2: Experiment confirming the antiviral efficacy of the polymer nanodisc of the present invention containing ACE2]
본 실시예에서는 기존 나노디스크의 막구조화 단백질(membrane scaffoldprotein, MSP)을 폴리머 성분으로 대체하여 제조하였음에도 기존 나노디스크처럼 우수한 항바이러스 효능을 보이는지 확인하고자 했다.In this example, we wanted to confirm whether the existing nanodisc showed excellent antiviral efficacy like the existing nanodisc even though it was manufactured by replacing the membrane scaffold protein (MSP) of the existing nanodisc with a polymer component.
이를 위해, 293T 세포에 ACE2 및 TMPRSS2(Transmembrane protease serine subtype 2)를 동시에 발현시킨 세포인 "HEK293-ACE2/TMPRSS2"에, 코로나(SARS-CoV-2)-슈도바이러스(PV)의 감염 정도를 정량하는 방법으로 바이러스 저해능을 평가하였다. 한편, 대조군으로는 폴리머 성분이 아닌 막구조화 단백질(membrane scaffoldprotein, MSP)로 제조한, ACE2가 포함된 나노디스크 (MSPNDA)로 설정하였다.For this purpose, the degree of infection of SARS-CoV-2-pseudovirus (PV) was quantified in “HEK293-ACE2/TMPRSS2”, which is a cell that simultaneously expressed ACE2 and TMPRSS2 (Transmembrane protease serine subtype 2) in 293T cells. The virus inhibition ability was evaluated using the following method. Meanwhile, the control group was set as a nanodisc containing ACE2 (MSPNDA), which was manufactured from membrane scaffold protein (MSP) rather than a polymer component.
구체적으로, 96개의 웰 플레이트에 293T 세포를 2 X 105 cell/ml 100 μL씩 분주하고 37℃, 5% CO2 인큐베이터에서 16시간 동안 배양하였다. 한편, 약물(나노디스크 농축액)과 코로나-슈도바이러스(1×105 RLU, Relative Light Unit)의 비율이 1:2가 되도록 혼합하되, 약물의 농도는 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)의 농도를 기준으로 하여, 100 μM부터 희석하며 혼합하였고, 37℃, 5% CO2 인큐베이터에서 1시간 동안 반응시켰다. 이후, 293T 세포가 있는 96개의 웰 플레이트에, 1시간 동안 반응시킨 '나노디스크 + 바이러스 혼합액'을 처리한 후, 37℃, 5% CO2 인큐베이터에서 48 시간 동안 배양하였다. 배양 후 세포에서 배지를 걷어내고, 1X CCLR(Cell Culture Lysis Reagent, Promega, 미국)를 각 웰당 10μL씩 처리하였다. 이후 Luciferase assay buffer(Promega, 미국) 100μL씩 처리한 후 스펙트로미터로 발광 값을 측정하여 본 발명 폴리머 나노디스크의 항바이러스 효능을 확인할 수 있었다 (도 3).Specifically, 293T cells were dispensed at 2 Meanwhile, mix the drug (nanodisc concentrate) and coronavirus-pseudovirus (1×10 5 RLU, Relative Light Unit) at a ratio of 1:2, but the concentration of the drug is Angiotensin converting enzyme 2 (ACE2). ) was diluted and mixed starting from 100 μM, and reacted at 37°C in a 5% CO 2 incubator for 1 hour. Afterwards, a 96-well plate containing 293T cells was treated with the 'nanodisk + virus mixture' reacted for 1 hour, and then cultured in an incubator at 37°C and 5% CO 2 for 48 hours. After culturing, the medium was removed from the cells, and 10 μL of 1X CCLR (Cell Culture Lysis Reagent, Promega, USA) was added to each well. Afterwards, the antiviral efficacy of the polymer nanodisc of the present invention was confirmed by treating the luciferase assay buffer (Promega, USA) with 100 μL each and measuring the luminescence value with a spectrometer (Figure 3).
이를 통해, 막구조화 단백질(membrane scaffoldprotein, MSP)을 폴리머 성분으로 대체한 본 발명의 폴리머 나노디스크 (SMANDA)도 MSPNDA처럼 코로나 바이러스에 대하여 우수한 항바이러스 효능을 보이는 것을 확인할 수 있었다. 게다가, 양친매성 폴리머로 스티렌과 말레산을 2:1의 중량비율로 사용한 경우 (SMANDA 2:1)는, MSP로 만든 나노디스크 (MSPNDA)와 거의 비슷한 항바이러스 효능을 보임을 확인할 수 있었다.Through this, it was confirmed that the polymer nanodisc (SMANDA) of the present invention, which replaces membrane scaffold protein (MSP) with a polymer component, also shows excellent antiviral efficacy against coronavirus like MSPNDA. In addition, when styrene and maleic acid were used as an amphiphilic polymer at a weight ratio of 2:1 (SMANDA 2:1), it was confirmed that the antiviral efficacy was almost similar to that of nanodiscs made from MSP (MSPNDA).

Claims (7)

  1. 인지질을 사용하여 형성된 납작한 원반 형태의 이중층 구조로서, 친수성기는 외부로 배향되고, 소수성기는 내부로 배향되어 있는 지질 이중층 (lipid bilayer); A lipid bilayer, a flat disk-shaped bilayer structure formed using phospholipids, in which the hydrophilic groups are oriented on the outside and the hydrophobic groups are oriented on the inside;
    상기 지질 이중층의, '소수성기가 외부로 노출되어 있는 측면'을 소수성 결합으로 둘러싸는 양친매성 폴리머 (amphipathic polymer); 및 an amphipathic polymer that surrounds the ‘side where the hydrophobic group is exposed to the outside’ of the lipid bilayer with a hydrophobic bond; and
    상기 지질 이중층 내부와 소수성 결합되는 안지오텐진 전환효소 2 (Angiotensin converting enzyme 2, ACE2)를 포함하는 것을 특징으로 하는 폴리머 나노디스크. A polymer nanodisc comprising angiotensin converting enzyme 2 (ACE2) hydrophobically bound to the inside of the lipid bilayer.
  2. 제1항에 있어서,According to paragraph 1,
    상기 안지오텐신 전환효소 2 (Angiotensin converting enzyme 2, ACE2)는, The angiotensin converting enzyme 2 (ACE2) is,
    트랜스멤브레인 도메인 (transmembrane domain)이 지질 이중층의 소수성 부위에 결합되어 있는 것을 특징으로 하는 폴리머 나노디스크. A polymer nanodisc characterized by a transmembrane domain bound to a hydrophobic region of a lipid bilayer.
  3. 제1항에 있어서,According to paragraph 1,
    상기 인지질은,The phospholipids are,
    포스파티딜콜린(phosphatidylcholine), 포스파티딜세린(phosphatidylserine), 포스파티딜에탄올아민(phophatidylethalolamine), 포스파티딜글리세롤(phophatidylglycerol) 및 포스파티딜이노시톨(phophatidylinositol) 중 선택되는 하나 이상인 것을 특징으로 하는 폴리머 나노디스크. A polymer nanodisk characterized in that it is one or more selected from phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phophatidylglycerol, and phosphatidylinositol.
  4. 제1항에 있어서,According to paragraph 1,
    상기 인지질은,The phospholipids are,
    DMPC(1,2-dimyristoyl-sn-glycero-3-phosphocholine), DPPC(1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DSPC(1,2-distearoyl-sn-glycero-3-phosphocholine), POPC(l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPS(1,2-dioleoyl-sn-glycero-3-phospho-L-serine), 및 POPE(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) 중 선택되는 어느 하나 이상을 포함하는 것을 특징으로 하는 폴리머 나노디스크. DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) , POPC (l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine), and POPE (1-palmitoyl-2- A polymer nanodisk characterized in that it contains at least one selected from oleoyl-sn-glycero-3-phosphoethanolamine).
  5. 제1항에 있어서,According to paragraph 1,
    상기 양친매성 폴리머 (amphipathic polymer)는,The amphipathic polymer is,
    스티렌-말레산(Styrene-Maleic Acid, SMA), 디-이소부틸렌-말레산(Di-IsoButylene-Maleic Acid, DIBMA), 스티렌-말레이미드(Styrene-Maleimide, SMI), 폴리메타크릴레이트(Polymethyl Methacrylate, PMA) 중 선택되는 어느 하나 이상인 것을 특징으로 하는 폴리머 나노디스크. Styrene-Maleic Acid (SMA), Di-IsoButylene-Maleic Acid (DIBMA), Styrene-Maleimide (SMI), Polymethacrylate (Polymethyl Methacrylate, PMA). A polymer nanodisk characterized in that it is one or more selected from the group consisting of:
  6. 제1항에 있어서,According to paragraph 1,
    상기 안지오텐신 전환효소 2는,The angiotensin converting enzyme 2,
    수용성 안지오텐신 전환효소 2인 것을 특징으로 하는 폴리머 나노디스크. Polymer nanodisc characterized by water-soluble angiotensin converting enzyme 2.
  7. 제1항의 폴리머 나노디스크를 포함하는 것을 특징으로 하는 바이러스 감염증 예방 또는 치료용 약학조성물 A pharmaceutical composition for preventing or treating viral infections, comprising the polymer nanodisc of claim 1.
PCT/KR2023/013151 2022-10-19 2023-09-04 Polymer nanodiscs comprising angiotensin-converting enzyme 2 and antiviral use thereof WO2024085427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0135213 2022-10-19
KR1020220135213A KR102540331B1 (en) 2022-10-19 2022-10-19 Polymer nanodisc with angiotensin converting enzyme 2 and its antiviral usage

Publications (1)

Publication Number Publication Date
WO2024085427A1 true WO2024085427A1 (en) 2024-04-25

Family

ID=86760714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/013151 WO2024085427A1 (en) 2022-10-19 2023-09-04 Polymer nanodiscs comprising angiotensin-converting enzyme 2 and antiviral use thereof

Country Status (2)

Country Link
KR (1) KR102540331B1 (en)
WO (1) WO2024085427A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102540331B1 (en) * 2022-10-19 2023-06-07 성균관대학교산학협력단 Polymer nanodisc with angiotensin converting enzyme 2 and its antiviral usage

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101994279B1 (en) * 2017-11-03 2019-06-28 서울대학교산학협력단 Manufacturing method of nanodisc comprising an olfactory receptor protein and nanodisc comprising an olfactory receptor protein manufactured by the same
KR102181991B1 (en) * 2016-07-15 2020-11-23 성균관대학교산학협력단 Nano-perforator and pharmaceutical composition comprising the same for preventing or treating viral infection
KR20210035752A (en) * 2019-09-24 2021-04-01 성균관대학교산학협력단 Nano-perforator having enhanced antiviral activity
KR20210123235A (en) * 2020-04-02 2021-10-13 조선대학교산학협력단 Use of ACE2 as treatment of COVID-19
KR102438720B1 (en) * 2022-02-21 2022-08-31 성균관대학교산학협력단 Nanodisc with angiotensin converting enzyme 2 and its antiviral usage
KR102540331B1 (en) * 2022-10-19 2023-06-07 성균관대학교산학협력단 Polymer nanodisc with angiotensin converting enzyme 2 and its antiviral usage

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102181991B1 (en) * 2016-07-15 2020-11-23 성균관대학교산학협력단 Nano-perforator and pharmaceutical composition comprising the same for preventing or treating viral infection
KR101994279B1 (en) * 2017-11-03 2019-06-28 서울대학교산학협력단 Manufacturing method of nanodisc comprising an olfactory receptor protein and nanodisc comprising an olfactory receptor protein manufactured by the same
KR20210035752A (en) * 2019-09-24 2021-04-01 성균관대학교산학협력단 Nano-perforator having enhanced antiviral activity
KR20210123235A (en) * 2020-04-02 2021-10-13 조선대학교산학협력단 Use of ACE2 as treatment of COVID-19
KR102438720B1 (en) * 2022-02-21 2022-08-31 성균관대학교산학협력단 Nanodisc with angiotensin converting enzyme 2 and its antiviral usage
KR102540331B1 (en) * 2022-10-19 2023-06-07 성균관대학교산학협력단 Polymer nanodisc with angiotensin converting enzyme 2 and its antiviral usage

Also Published As

Publication number Publication date
KR102540331B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
WO2024085427A1 (en) Polymer nanodiscs comprising angiotensin-converting enzyme 2 and antiviral use thereof
US11541100B2 (en) Pharmaceutical composition comprising nanoperforator for preventing or treating viral infectious diseases
US6037348A (en) Inhibition of viral replication
WO2024085693A1 (en) Nanodisc comprising phosphatidylethanolamine phospholipid
WO2021151100A1 (en) Methods, compositions, and vaccines for treating a virus infection
US20090186101A1 (en) Use of Elderberry Extract
EP3892269B1 (en) Probenecid for treating coronavirus infections
US20200330487A1 (en) Prevention and treatment of flu-type viral infections and related complications
CN114377127B (en) Triple egg yolk antibody preparation and preparation method and application thereof
US20230218663A1 (en) Compositions and methods for treating a sars-cov-2 infection
WO2009089534A2 (en) Compositions and methods for the treatment of viral infections caused by influenza virus
US11090315B1 (en) Prevention and treatment of flu-type viral infections and related complications
CN111773182B (en) Compound preparation for preventing virus infection and preparation/use method and application thereof
WO2024010367A1 (en) Nanodisc comprising membrane scaffold protein having fc region of antibody fused thereto
WO2023158158A1 (en) Nanodisc comprising angiotensin converting enzyme 2 and antiviral use thereof
WO2023158159A1 (en) Nanodisc comprising angiotensin converting enzyme 2
US20240197634A1 (en) Pharmaceutical composition for preventing or treating virus infections, comprising polymer nanodiscs
WO2021003365A1 (en) Compositions and methods useful for ebola virus infection
US20230165936A1 (en) Compositions of anti-viral peptides and methods of use thereof
KR20240007070A (en) Nanodisc containing membrane scaffold protein fused with Fc region of antibody
TWI807410B (en) Method for inhibiting coronavirus and method for treating disease associated with coronavirus infection
EP4232460A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
WO2022000167A1 (en) Use of transferrin, transferrin receptor and antibody thereof in preparation of drug for resisting sars-cov-2 virus
RU2443431C1 (en) Method for preventing and treating influenza in pre-epidemic and epidemic environment and related drug preparation for implementation thereof
Liu Electroporation Mediated Gene Delivery to Rescue the Alveolar Capillary Barrier Function for ARDS Treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23880007

Country of ref document: EP

Kind code of ref document: A1